Overview

Trial of CPX-351 in Newly Diagnosed Elderly AML Patients

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The study investigates if CPX-351 will be a) more effective than the standard AML treatment and b) more tolerable than the standard AML treatment regimens. The study compares the investigational product CPX-351 vs the standard treatment for AML in this patients age group.
Phase:
Phase 2
Details
Lead Sponsor:
Celator Pharmaceuticals
Jazz Pharmaceuticals
Treatments:
Cytarabine
Daunorubicin